Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 15/20 | 0.58 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.58 |
| ▸ | PIK3C2A | O00443 | 3/20 | 0.58 |
| ▸ | PIK3C2B | O00750 | 3/20 | 0.58 |
| ▸ | PIK3CD | O00329 | 9/20 | 0.57 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.57 |
| ▸ | PIK3CB | P42338 | 6/20 | 0.57 |
| ▸ | PRKDC | P78527 | 3/20 | 0.57 |
| ▸ | PIK3C3 | Q8NEB9 | 3/20 | 0.57 |
| ▸ | ATM | Q13315 | 2/20 | 0.57 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.57 |
| ▸ | RPTOR | Q8N122 | 2/20 | 0.57 |
| ▸ | MLST8 | Q9BVC4 | 2/20 | 0.57 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.57 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.57 |
| ▸ | CSF1R | P07333 | 1/20 | 0.57 |
| ▸ | MET | P08581 | 1/20 | 0.57 |
| ▸ | LTK | P29376 | 1/20 | 0.57 |
| ▸ | CDK7 | P50613 | 1/20 | 0.57 |
| ▸ | NEK2 | P51955 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL927762 | 1.00 | MTOR (0.58) | MTORPIK3CAPIK3C2APIK3C2BPIK3CD | |
| SCHEMBL995049 | 0.90 | MTOR (0.64) | MTORPIK3CAPIK3C2APIK3C2BPIK3CD | |
| SCHEMBL995051 | 0.90 | MTOR (0.64) | MTORPIK3CAPIK3C2APIK3C2BPIK3CD | |
| SCHEMBL927283 | 0.88 | MTOR (0.61) | MTORPIK3CAPIK3C2APIK3C2BPIK3CD | |
| SCHEMBL927316 | 0.88 | MTOR (0.65) | MTORPIK3CAPIK3C2APIK3C2BPIK3CD | |
| SCHEMBL927752 | 0.88 | ATM (0.52) | MTORPIK3CAPIK3C2APIK3C2BPIK3CD | |
| SCHEMBL927751 | 0.88 | ATM (0.52) | MTORPIK3CAPIK3C2APIK3C2BPIK3CD | |
| SCHEMBL928839 | 0.87 | MTOR (0.66) | MTORPIK3CAPIK3CDPIK3CGPIK3CB | |
| SCHEMBL928837 | 0.87 | MTOR (0.66) | MTORPIK3CAPIK3CDPIK3CGPIK3CB | |
| SCHEMBL929485 | 0.85 | MTOR (0.55) | MTORPIK3CAPIK3C2APIK3C2BPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2270008-B1 | 8-heteroaryl-3-alkyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as PI-3 kinases inhibitors | NOVARTIS AG (CH) | 2012-10-03 | — | — | EP | claimed |
| US-7994170-B2 | 1,3-dihydro-imidazo[4,5-C]quinolin-2-ones as lipid kinase inhibitors | NOVARTIS AG (CH) | 2011-08-09 | — | — | US | claimed |
| EP-2292617-A1 | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinase inhibitors | Novartis AG (CH) | 2011-03-09 | — | — | EP | claimed |
| EP-2270008-A1 | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinases inhibitors | Novartis AG (CH) | 2011-01-05 | — | — | EP | claimed |
| US-20100056558-A1 | 1,3-DIHYDRO-IMIDAZO[4,5-C]QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | claimed |
| US-20080194579-A1 | 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors | NOVARTIS AG (CH) | 2008-08-14 | — | — | US | claimed |
| US-9370508-B2 | Imidazoquinolines as dual lipid kinase and mTOR inhibitors | NOVARTIS AG (CH) | 2016-06-21 | — | — | US | disclosed |
| US-20130178479-A1 | PHARMACEUTICAL COMBINATIONS | NOVARTIS AG (CH) | 2013-07-11 | — | — | US | disclosed |
| US-8431592-B2 | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase inhibitors | NOVARTIS AG (CH) | 2013-04-30 | — | — | US | disclosed |
| US-20120282252-A1 | 5Imidazoquinolines and Pyrimidine Derivatives as Potent Modulators of VEGF-Driven Angiogenic Processes | NOVARTIS AG (CH) | 2012-11-08 | — | — | US | disclosed |
| EP-2270008-B1 | 8-heteroaryl-3-alkyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as PI-3 kinases inhibitors | NOVARTIS AG (CH) | 2012-10-03 | — | — | EP | disclosed |
| US-20120207751-A1 | Imidazoquinolines as lipid kinase inhibitors | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| EP-2474323-A2 | Imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes | Novartis AG (CH) | 2012-07-11 | — | — | EP | disclosed |
| EP-2292617-A1 | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinase inhibitors | Novartis AG (CH) | 2011-03-09 | — | — | EP | disclosed |
| US-20110020338-A1 | 5Imidazoquinolines and Pyrimidine Derivatives as Potent Modulators of VEGF-Driven Angiogenic Processes | NOVARTIS AG (CH) | 2011-01-27 | — | — | US | disclosed |
| EP-2270008-A1 | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinases inhibitors | Novartis AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| US-20100105696-A1 | IMIDAZOQUINOLINES AS DUAL LIPID KINASE AND mTOR INHIBITORS | NOVARTIS AG (CH) | 2010-04-29 | — | — | US | disclosed |
| US-20100056558-A1 | 1,3-DIHYDRO-IMIDAZO[4,5-C]QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | disclosed |
| US-7667039-B2 | 1,3-dihydro-imidazo [4,5-C] quinolin-2-ones as lipid kinase inhibitors | NOVARTIS AG (CH) | 2010-02-23 | — | — | US | disclosed |
| US-20080194579-A1 | 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors | NOVARTIS AG (CH) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105696-A1 | IMIDAZOQUINOLINES AS DUAL LIPID KINASE AND mTOR INHIBITORS | MTOR, ULK1, RICTOR | MTOR 1/4885PIK3CA 34/4885PIK3C2A 19/4885 |
| US-20100056558-A1 | 1,3-DIHYDRO-IMIDAZO[4,5-C]QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS | PDPK1, PI4KA, PIP4K2A | MTOR 89/4885PIK3CA 8/4885PIK3C2A 12/4885 |
| US-20120207751-A1 | Imidazoquinolines as lipid kinase inhibitors | PI4KA, PDPK1, PI4KB | MTOR 171/4885PIK3CA 29/4885PIK3C2A 64/4885 |
| US-20130178479-A1 | PHARMACEUTICAL COMBINATIONS | MTOR, RICTOR, PIK3CA | MTOR 1/4885PIK3CA 3/4885PIK3C2A 7/4885 |
| US-20120282252-A1 | 5Imidazoquinolines and Pyrimidine Derivatives as Potent Modulators of VEGF-Driven Angiogenic Processes | KDR, FLT4, TEK | MTOR 2286/4885PIK3CA 1091/4885PIK3C2A 2258/4885 |
| US-20080194579-A1 | 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors | PDPK1, PI4KA, PIP4K2A | MTOR 89/4885PIK3CA 8/4885PIK3C2A 12/4885 |
| US-20110020338-A1 | 5Imidazoquinolines and Pyrimidine Derivatives as Potent Modulators of VEGF-Driven Angiogenic Processes | KDR, FLT4, TEK | MTOR 2286/4885PIK3CA 1091/4885PIK3C2A 2258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.